Drug intelligence / Profile preview

OCB-30

Development stage: Discontinued
Lead developer: Arbutus Biopharma
Modality: Small Molecules
Administration: Oral

Overview

OCB-30 is an oral dosage form, sanglifehrin-based cyclophilin inhibitor that was being developed for the treatment of Hepatitis B virus (HBV) infection. It was initially developed by Arbutus Inc. (later Arbutus Biopharma) and licensed to NeuroVive Pharmaceutical AB for further development, manufacturing, and commercialization. However, Arbutus discontinued its development program for OCB-30 in 2015, and the license agreement with NeuroVive was terminated in 2016.

Targets

Cyp (Cyclophilin family)

Beyond the preview

Go deeper on OCB-30.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCB-30.

Explore the full profile